TP53 and neoplasm: The amplification and overexpression of MDMX in breast cancer have also been confirmed in Nottingham/Tenovus cohort with a well-characterized series of 990 cases and other studies and have been associated with p53 mutation, breast carcinogenesis, invasive disease, small tumor size, low grade, longer breast carcinoma specific survival (BCSS), and disease-free survival (DFS) (62–65).